Time: 8:30 am ET Dial-in numbers: (866) 501-1521 (U.S. and Canada) or (760) 536-8586 (international) Conference ID#: 22090693 Live webcast: www.catalystpharma.com , under "Events"
The teleconference replay will be available three hours after completion through November 5, 2010 at (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (international). The replay pass code is 22090693. The archived webcast will be available for one year.
CPP-115 is the lead compound being developed by Catalyst under its license agreement with Northwestern University. Dr. Richard B. Silverman, the John Evans Professor of Chemistry at Northwestern University, led the team of scientists that invented CPP-115. Dr. Silverman holds 41 patents and is the inventor of pregabalin (Lyrica ®). He is the recipient of numerous awards, most recently the 2009 Perkin Medal, has published over 250 peer reviewed articles, and has written four books over his 33 year career in academia. Complete details of Dr. Silverman's achievements can be found at http://chemgroups.northwestern.edu/silverman.About Cheryl Craft, Ph.D. Dr. Craft, who consults with Catalyst on eye safety issues, is a noted expert in the fields of retinal molecular and cell biology, gene regulation of retinal function, and the physiological and histological evaluation of the retina in health and disease. Dr. Craft is a co-author of the published work upon which CPP-115's method of visual safety evaluation is based. Dr. Craft's complete work and accomplishments can be found at http://www.usc.edu/programs/neuroscience/faculty/profile.php?fid=9 . About Catalyst Pharmaceutical Partners Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system, such as epilepsy and neuropathic pain. Catalyst has two GABA aminotransferase inhibitors in development, CPP-109 (vigabatrin) and CPP-115. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase inhibition. For more information about the Company, go to www.catalystpharma.com . Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown `risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-115 will ultimately be determined to be a safe and effective treatment for epilepsy or stimulant addiction, whether Catalyst has sufficient funds to complete the remaining non-clinical studies required to file an IND for CPP-115 and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: Catalyst Pharmaceutical Partners, Inc. Patrick J. McEnany, Chief Executive Officer (305) 529-2522 email@example.com Rx Communications Group Melody Carey, Co-President (917) 322-2571 firstname.lastname@example.org